Robotic gloveless isolator technology enhances regional production of advanced therapeutics

DOI: 10.18609/cgti.2025.022

Cell & Gene Therapy Insights 2025; 11(2), 175–181

Published: 27 February
Innovator Insight
Zach Hartman, Peter Boman

The increasing complexity of advanced therapy manufacturing, driven by smaller batch sizes, higher drug substance cost, and stricter regulatory guidelines, necessitates a shift toward more agile and precise production systems. Robotic gloveless isolator (RGI) technology addresses critical challenges in aseptic fill-finish operations by minimizing contamination risk and product loss, particularly for sensitive modalities such as plasmid DNA, viral vectors, mRNA, and recombinant proteins.